Valeritas (VLRX) Reaches New 12-Month Low at $1.16
Valeritas Holdings Inc (NASDAQ:VLRX) hit a new 52-week low on Thursday . The stock traded as low as $1.16 and last traded at $1.22, with a volume of 4166 shares traded. The stock had previously closed at $1.29.
Several equities research analysts recently weighed in on VLRX shares. Oppenheimer set a $4.00 price target on shares of Valeritas and gave the stock a “buy” rating in a research report on Tuesday, August 7th. started coverage on shares of Valeritas in a research report on Thursday, July 5th. They issued an “outperform” rating and a $3.50 price target on the stock. ValuEngine upgraded shares of Valeritas from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Citigroup started coverage on shares of Valeritas in a research report on Thursday, July 5th. They issued an “outperform” rating and a $3.50 price target on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $3.67.
The company has a debt-to-equity ratio of 13.66, a quick ratio of 3.42 and a current ratio of 4.03. The stock has a market cap of $32.56 million, a price-to-earnings ratio of -0.15 and a beta of 4.55.
A number of hedge funds have recently bought and sold shares of VLRX. Essex Investment Management Co. LLC bought a new position in Valeritas during the second quarter valued at $448,000. Bainco International Investors bought a new position in Valeritas during the second quarter valued at $228,000. Finally, C WorldWide Group Holding A S increased its position in Valeritas by 28.0% during the second quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after acquiring an additional 69,216 shares during the last quarter. Institutional investors and hedge funds own 4.32% of the company’s stock.
About Valeritas (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Recommended Story: Diversification in Investing
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.